Kimberly-Clark Corporation (LON:0JQZ)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 24.72B -19.1% |
| Revenue (ttm) | 12.50B +0.7% |
| Net Income | 1.47B -19.5% |
| EPS | 4.42 -19.4% |
| Shares Out | n/a |
| PE Ratio | 16.78 |
| Forward PE | 14.06 |
| Dividend | 3.85 (5.23%) |
| Ex-Dividend Date | Sep 4, 2026 |
| Volume | 2,686 |
| Open | 99.11 |
| Previous Close | 97.47 |
| Day's Range | 96.69 - 99.11 |
| 52-Week Range | 92.39 - 124.95 |
| Beta | 0.27 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Oct 20, 2026 |
About Kimberly-Clark
Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care products in the United States. It operates in two segments, North America and International Personal Care. The North America segment offers disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear, facial and bathroom tissue, paper towels, napkins, wipers, tissue, towels, soaps and sanitizers, and other related products under the Huggies, Pull-Ups, Goodnites, Kotex, Poise, Dep... [Read more]
Financial Performance
In 2025, Kimberly-Clark's revenue was $16.45 billion, a decrease of -2.13% compared to the previous year's $16.81 billion. Earnings were $2.02 billion, a decrease of -20.59%.
Financial numbers in USD Financial StatementsNews
Kimberly-Clark price target lowered to $120 from $122 at BofA
BofA lowered the firm’s price target on Kimberly-Clark (KMB) to $120 from $122 and keeps a Buy rating on the shares. The firm reduced its Q3 organic sales estimate to…
Kimberly-Clark offers remedies in bid for EU approval of Kenvue deal
Kimberly-Clark has offered concessions to address EU antitrust concerns about its $40 billion bid for Tylenol maker Kenvue , a filing on the European Commission website showed on Wednesday.
Kimberly-Clark readying asset sales for Kenvue deal EU approval, Reuters says
Kimberly-Clark (KMB) is preparing concessions to address EU antitrust concerns over its roughly $40B acquisition of Kenvue (KVUE), potentially clearing the way for regulatory approval after the Europe...
Kimberly-Clark readies EU remedies in bid for Kenvue deal, sources say
Kimberly-Clark is readying concessions to address EU antitrust concerns about its bid for Tylenol maker Kenvue that could help it win approval for the $40 billion deal after a preliminary review,...
My Favorite Consumer Staples Play Right Now
Owning consumer staples stocks is an absolute must in a dividend investing strategy. Most people turn to dividend stocks for two reasons — to generate income or to put the magic of compounding to work...
Kimberly-Clark price target lowered to $118 from $121 at Piper Sandler
Piper Sandler lowered the firm’s price target on Kimberly-Clark (KMB) to $118 from $121 and keeps an Overweight rating on the shares. The firm is updating its Q3 estimates to…
Kimberly-Clark price target lowered to $105 from $110 at Wells Fargo
Wells Fargo lowered the firm’s price target on Kimberly-Clark (KMB) to $105 from $110 and keeps an Equal Weight rating on the shares. The firm says the company’s EPS is…
Kimberly-Clark Transcript: Barclays 19th Annual Global Consumer Conference
Powering Care strategy has driven consistent growth, margin expansion, and reduced volatility, with premiumization and innovation as key levers. Despite near-term headwinds from China, logistics, and cost inflation, long-term growth and synergy opportunities from the Kenvue acquisition and the Suzano JV remain robust.
Huggies® Rallies Communities to Recognize the Fighting Spirit of NICU Babies During NICU Awareness Month
Huggies renames its nano and micro preemie diapers "Huggies Little Fighters" and marks NICU Awareness Month by spotlighting real stories and supporting families CHICAGO, Sept. 3, 2026 /PRNewswire/ -- ...
Australia clears Kimberly-Clark's acquisition of Kenvue but requires Carefree, Stayfree divestment
Australia's competition regulator on Wednesday approved Kimberly-Clark's proposed $40 billion takeover of Kenvue , on condition the company divests Kenvue's Carefree and Stayfree period care brands ...
Kimberly-Clark to Webcast its Presentation at Barclays 19th Annual Global Consumer Staples Conference
DALLAS, Sept. 1, 2026 /PRNewswire/ -- Mike Hsu, Chairman and CEO of Kimberly-Clark Corporation (NASDAQ: KMB), Russ Torres, President and Chief Operating Officer, and Nelson Urdaneta, Chief Financial O...
Kimberly-Clark seeking EU approval for $40B Kenvue takeover, Reuters reports
Kimberly-Clark (KMB) has asked EU regulators permission for its proposed $40B takeover of Kenvue (KVUE), Reuters’ Bart Meijer reports. Kimberly-Clark announced the takeover in November 2025, and the d...
Kimberly-Clark seeks EU approval for $40 billion Kenvue deal
Kimberly-Clark has asked EU regulators permission for its proposed $40 billion takeover of Tylenol maker Kenvue, documents on the EU Commission's website showed.
Kimberly-Clark names Suzana Blades as SVP, General Counsel
Kimberly-Clark (KMB) announced the appointment of Suzana Blades as Senior Vice President and General Counsel, effective September 1. She will report to Jeff Melucci, Chief Strategy, Business Developme...
Kimberly-Clark Appoints Suzana Blades as Senior Vice President and General Counsel
Accomplished legal executive and global litigator brings proven track record of enterprise risk management and strategic leadership to support Kimberly-Clark's next chapter of growth DALLAS, Aug. 13, ...
Kimberly-Clark price target raised to $104 from $96 at TD Cowen
TD Cowen raised the firm’s price target on Kimberly-Clark (KMB) to $104 from $96 and keeps a Hold rating on the shares. The firm said Kimberly-Clark lowered FY27 guidance and…
Kimberly-Clark price target raised to $116 from $115 at UBS
UBS analyst Peter Grom raised the firm’s price target on Kimberly-Clark (KMB) to $116 from $115 and keeps a Neutral rating on the shares.
Kimberly-Clark price target raised to $112 from $106 at Deutsche Bank
Deutsche Bank analyst Steve Powers raised the firm’s price target on Kimberly-Clark (KMB) to $112 from $106 and keeps a Hold rating on the shares.
Kimberly-Clark price target raised to $122 from $120 at BofA
BofA raised the firm’s price target on Kimberly-Clark (KMB) to $122 from $120 and keeps a Buy rating on the shares. The firm, which cites improving peer multiples for its…
Kimberly-Clark upgraded to Buy from Hold at Freedom Broker
Freedom Broker analyst Georgy Vashchenko upgraded Kimberly-Clark (KMB) to Buy from Hold with an unchanged price target of $121. The firm views the company’s Q2 report as mixed. The quarter…
Kimberly-Clark Earnings Call Transcript: Q2 2026
Q2 saw solid execution and productivity gains, offsetting headwinds from China disruption and North America inventory reductions. Adjusted operating profit and EPS exceeded expectations, aided by a tariff refund, while innovation and integration initiatives advanced. Guidance reflects ongoing input cost and China-related challenges.
Kimberly-Clark Earnings release: Q2 2026
Kimberly-Clark released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Kimberly-Clark Slides: Q2 2026
Kimberly-Clark has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Kimberly-Clark Quarterly report: Q2 2026
Kimberly-Clark has published its Q2 2026 quarterly earnings report on August 4, 2026.